Source:http://linkedlifedata.com/resource/pubmed/id/12492710
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2002-12-20
|
pubmed:abstractText |
In phase III trials daclizumab was used in a five-dose regimen of 1 mg/kg at 2-weekly intervals, resulting in saturation of IL-2Ralpha on circulating lymphocytes for up to 120 days after renal transplantation. The purpose of this study was to evaluate daclizumab blood concentrations and the saturation of the IL-2Ralpha on the circulating lymphocytes with a limited dosing regimen of daclizumab. Twelve patients undergoing primary cadaver or living donor transplantation were randomized to either receive one dose (2 mg/kg) or two doses (2nd dose, 1 mg/kg) of daclizumab in addition to maintenance immunosuppression therapy consisting of either tacrolimus or cyclosporine, mycophenolate mofetil and prednisone. Patients were followed for 6 months after the transplantation. Pharmacokinetic and pharmacodynamic studies were performed up to 20 weeks after the transplantation. In patients treated with a single dose of daclizumab, the blood concentrations of daclizumab declined to 1 micro g/mL at 43 +/- 7 days after the transplantation. In patients treated with two doses of daclizumab, the blood concentrations of daclizumab declined to 1 micro g/mL at 45 +/- 13 days after the second dose for a total of 59 +/- 13 days after the transplantation. Daclizumab levels of 1 micro g/mL or greater were associated with saturation of the IL-2Ralpha on the circulating lymphocytes. In the new era of effective maintenance immunosuppression, a limited dosing regimen of daclizumab may be desired, practical and economical.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/IL2RA protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin G,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2 Receptor alpha Subunit,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Interleukin,
http://linkedlifedata.com/resource/pubmed/chemical/daclizumab
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
1600-6135
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
3
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
50-2
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:12492710-Antibodies, Monoclonal,
pubmed-meshheading:12492710-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:12492710-Graft Rejection,
pubmed-meshheading:12492710-Humans,
pubmed-meshheading:12492710-Immunoglobulin G,
pubmed-meshheading:12492710-Immunosuppressive Agents,
pubmed-meshheading:12492710-Interleukin-2 Receptor alpha Subunit,
pubmed-meshheading:12492710-Kidney Transplantation,
pubmed-meshheading:12492710-Receptors, Interleukin,
pubmed-meshheading:12492710-Transplantation, Homologous,
pubmed-meshheading:12492710-Treatment Outcome
|
pubmed:year |
2003
|
pubmed:articleTitle |
Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation.
|
pubmed:affiliation |
University of California, San Francisco, CA, USA. vincentif@surgery.ucsf.edu
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Clinical Trial, Phase III
|